EBioMedicine:改变多巴胺信号或可治疗自闭症

2015-02-02 佚名 生物谷

刊登在国际杂志EbioMedicine上的一篇研究报告中,来自美国纳什维尔凡德比大学医学中心(Vanderbilt University Medical Center)的科学家发现,和自闭症谱系障碍(ASD)相关的遗传改变会改变多巴胺转运蛋白的功能,这就表明,多巴胺信号的改变会引发常见的发育问题。 本文研究首次发现在果蝇模型中两种不同的ASD相关遗传改变会产生相同的神经和行为改变,研究人员开发了

刊登在国际杂志EbioMedicine上的一篇研究报告中,来自美国纳什维尔凡德比大学医学中心(Vanderbilt University Medical Center)的科学家发现,和自闭症谱系障碍(ASD)相关的遗传改变会改变多巴胺转运蛋白的功能,这就表明,多巴胺信号的改变会引发常见的发育问题。

本文研究首次发现在果蝇模型中两种不同的ASD相关遗传改变会产生相同的神经和行为改变,研究人员开发了一种小鼠模型证实了他们的发现,同时他们也联合生物药剂学的研究者来以多巴胺转运蛋白为靶点开发治疗ASD的新型疗法。Galli博士表示,我们目前正在寻找一种分子网络来以不同的方式干扰多巴胺的神经传递,但是有时候会发现相同的机制。

多巴胺是一种参与奖惩行为的神经递质,比如参与食欲调节、成瘾及社会关系等。这项研究中研究者对两个家族患ASD的患儿进行研究中在多巴胺转运蛋白基因和突触融合蛋白1基因(STX1)中鉴别出了遗传突变,突触融合蛋白1可以调节转运蛋白。在果蝇模型中模拟这两种遗传突变的分子特性就可以阻断苯丙胺诱导的运动,这就揭示了对药物苯丙胺行为反应的降低。

研究者最后指出,研究奖惩行为的最好模式就是运动,因为我们必须去运动才能获取食物,必须运动才能获取我们喜欢的东西;目前研究人员已经开始以完全不同的方式来对多巴胺转运蛋白进行研究了,研究人员希望后期可以更好地理解机体多巴胺能系统的发生机制,并且寻找可以靶向作用多巴胺能系统的方法,从而为治疗自闭症谱系障碍提供希望。

原始出处

Etienne Cartiera, 1, Peter J. Hamiltonb, c, 1, Andrea N.et.al.Rare Autism-Associated Variants Implicate Syntaxin 1 (STX1 R26Q) Phosphorylation and the Dopamine Transporter (hDAT R51W) in Dopamine Neurotransmission and Behaviors.EBioMedicine.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-11-24 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2016-01-08 linagood
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-07-13 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-07-23 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-02-04 xiongke014
  6. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1917125, encodeId=f2a5191e1255c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 24 12:11:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997067, encodeId=687c199e06728, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jan 08 20:11:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858599, encodeId=a60a1858599d8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jul 13 13:11:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773477, encodeId=c2fe1e7347781, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Jul 23 11:11:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527582, encodeId=09f7152e582bb, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577418, encodeId=97b815e741826, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606389, encodeId=0e22160638929, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 04 04:11:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]

相关资讯

Mol Psychiatry:嘿,胖纸,知道你为啥这么能吃么?

近日,刊登在国际杂志Molecular Psychiatry上的一篇研究报告中,来自美国国立卫生研究院的研究人员通过研究表示,由于大脑中促进饮食习惯及较少回报的脑部化学物质的差异,相比瘦弱个体来讲,肥胖个体对环境中的食物更加敏感。 文章中,研究人员对脂肪含量不同的43名男性和女性进行了研究,相比较瘦个体来讲,肥胖个体更易于在其大脑习惯形成区域积累较多的多巴胺活性,而在控制回报的区

Int J Cancer:抗血管生成药物多巴胺或可用于癌症治疗

近日,来自俄亥俄州立大学综合癌症研究中心的研究人员通过研究揭示,一种当前用于治疗心脏、血管及肾脏疾病的药物—多巴胺或许可以安全用于癌症治疗中,来遏制肿瘤组织血管的生长,相关研究发表于国际杂志International Journal of Cancer上。 文章中,研究者通过研究表明,多巴胺可以抑制两种动物模型机体血管的生长,同时并不会引发严重的副作用。此外,多巴胺还可以抑制因5-氟尿嘧啶引

Cell:多巴胺可能通过抑制NLRP3发挥抗炎作用

多巴胺是一种经典的中枢神经递质,由多巴胺能神经元合成并储存在囊泡中,可能是通过胞裂外排的方式由神经元释放。多巴胺作用于多巴胺受体,通过一系列反应,改变细胞膜对离子的通透性,从而产生生理作用。多巴胺有调节躯体活动、精神活动、内分泌和心血管活动的作用。多巴胺能神经元的病变可导致多种疾病,如帕金森病,精神分裂症等。 在五十年代以前,多巴胺一直被认为是合成去甲肾上腺素的前体。瑞典哥德堡大学教授阿维德

Int J Cancer:多巴胺或可用于5-FU引发中性粒细胞减少的治疗

近日,来自俄亥俄州立大学综合癌症研究中心的研究人员通过研究揭示,一种当前用于治疗心脏、血管及肾脏疾病的药物—多巴胺或许可以安全用于癌症治疗中,来遏制肿瘤组织血管的生长,相关研究发表于国际杂志International Journal of Cancer上。 文章中,研究者通过研究表明,多巴胺可以抑制两种动物模型机体血管的生长,同时并不会引发严重的副作用。此外,多巴胺还可以抑制因5-氟尿嘧啶引

性爱、多巴胺和世界杯:为什么我们爱足球

在一个周日的正午,我坐在拥挤的酒吧中,紧张的观看着美国队与葡萄牙队的比赛。记得当时球被解围出禁区,落到中场球员杰梅因·琼斯的脚下。对他来说,在那个位置直接射门有点太远了。琼斯刚触球,我旁边的一个家伙就咕哝着,“别射!”,他希望琼斯能把球传给有更好射门机会的队友。但琼斯抽射出了一记有力的弧线球,直撞边网入门。这一切都太快太突然了,门将甚至没做出扑救反应,站着目送球进。紧接着整个酒吧都欢呼了起来。

AHA 2013:小剂量多巴胺或奈西立肽未能改善急性心力衰竭患者肾功能(ROSE AHF研究)

2013年11月18日,美国心脏协会(AHA)2013科学年会公布的一项急性心衰肾脏最优策略评估(ROSE AHF)研究结果显示,小剂量多巴胺或奈西立肽未能改善急性心衰患者的肾功能。 ROSE AHF研究是一项多中心、双盲、对照、随机临床研究,360例伴肾功能不全的急性心衰(AHF)住院患者随机分为3组,分别给予小剂量多巴胺(2ug/kg/min)、小剂量奈西利肽(0.005ug/kg/mi